2020-10-27 16:00Financial Performance - Operating revenue for the first nine months was RMB 5,673,787.90, a 194.02% increase compared to the same period last year[5]. - Net loss attributable to shareholders was RMB -175,891,311.14, an increase in loss of 88.17% year-on-year[5]. - Total operating revenue for Q3 2020 was CNY 1,644,177.50, a significant increase from CNY 23,830.62 in Q3 2019[26]. - Net profit for Q3 2020 was a loss of CNY 73,689,564.89, worsening from a loss of CNY 23,780,346.34 in Q3 2019[28]. - The total comprehensive loss for Q3 2020 was CNY 73,689,564.89, compared to a loss of CNY 23,780,346.34 in Q3 2019[29]. - The company reported a total of CNY 15,259,170.67 in other income for Q3 2020, compared to CNY 1,966,890.49 in Q3 2019[27]. Assets and Liabilities - Total assets increased by 273.32% year-on-year, reaching RMB 6,661,918,047.53[5]. - The total liabilities of the company were reported at RMB 374,694,638.01, compared to RMB 313,981,998.88 in the previous year[22]. - The company's equity attributable to shareholders reached RMB 6,287,223,409.52, a substantial rise from RMB 1,470,516,717.61[22]. - The non-current assets totaled RMB 1,153,615,854.06, up from RMB 990,252,980.05, showing an increase of about 16.5%[21]. Cash Flow - Cash flow from operating activities showed a net outflow of RMB -171,971,392.16, worsening by 79.05% compared to the previous year[5]. - The cash flow from operating activities in Q3 2020 was negative at ¥171,971,392.16, compared to a negative cash flow of ¥96,046,989.70 in Q3 2019[34]. - The net cash flow from financing activities increased by 3,840,993,833.05 CNY, a growth of 349.09%, primarily due to increased funds raised from the public issuance of shares on the Shanghai Stock Exchange[17]. - The net cash flow from financing activities in Q3 2020 was ¥4,983,775,680.00, up from ¥1,127,769,646.18 in Q3 2019, showing strong financing efforts[34]. Research and Development - Research and development expenses accounted for 3,114.61% of operating revenue, a decrease of 1787.16 percentage points[6]. - Research and development expenses increased by 82,124,454.84 CNY, a growth of 86.82%, as the company continued to increase R&D investment to maintain technological and quality advantages[15]. - The company has ongoing investments in research and development, with development expenditures amounting to RMB 35,402,490.41[25]. - R&D expenses in Q3 2020 amounted to ¥68,793,725.13, up from ¥37,077,466.91 in Q3 2019, reflecting a 85.5% increase year-over-year[31]. Shareholder Information - The total number of shareholders at the end of the reporting period was 21,678[8]. - The largest shareholder, HKSCC NOMINEES LIMITED, held 39.63% of the shares[9]. Government Support - Government subsidies recognized in the current period amounted to RMB 15,259,170.67[7]. - Deferred income increased by 43,339,016.07 CNY, a growth of 72.48%, mainly due to the increase in government subsidies during the reporting period[15]. Inventory and Financial Assets - Trading financial assets increased by 3,491,483,965.90 CNY, a growth of 3130.64%, primarily due to the increase in structured deposits during the reporting period[14]. - Inventory increased by 44,625,295.55 CNY, a growth of 273.13%, mainly due to the increase in raw materials and turnover materials for R&D production during the reporting period[14].